Saniona AB (publ) (SANION.ST)
| Previous close | 2.3000 |
| Open | 2.2850 |
| Bid | 2.3250 x 0 |
| Ask | 2.3500 x 0 |
| Day's range | 2.2500 - 2.4250 |
| 52-week range | 1.5720 - 20.5000 |
| Volume | |
| Avg. volume | 1,539,730 |
| Market cap | 145.047M |
| Beta (5Y monthly) | 0.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.5900 |
| Earnings date | 25 May 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 77.50 |
- Globe Newswire
Saniona´s Clinical Trial in Hypothalamic Obesity Published in Scientific Journal
PRESS RELEASE May 23, 2022 Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that the results from the randomized controlled clinical trial of Tesomet for weight loss in patients with hypothalamic obesity has been published in the peer-reviewed scientific journal European Journal of Endocrinology. The conclusion is that the results are encouraging and support the continued investigation of Tesomet for the treatment of acquired hypothalami
- Globe Newswire
Saniona provides update on ongoing review of tesofensine in Mexico
PRESS RELEASE May 20, 2022 Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that the Mexican regulatory authority Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) has published on Twitter that its technical committee on new molecules (El Comité de Moléculas Nuevas) was unable to provide a favorable opinion on tesofensine following a meeting held on May 18, 2022. The statement on Twitter does not provide any detail
- Globe Newswire
Saniona publishes its Annual Report for 2021
PRESS RELEASE April 30, 2022 Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that the English version of the Annual Report for 2021 is now available on the company’s website, www.saniona.com. For more information, please contact Thomas Feldthus, incoming CEO, +45 22109957; thomas.feldthus@saniona.com This information was submitted for publication, through the agency of the contact person set out above, at 8.00 CEST on 30 April 2022. Abo
